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This progress report lists: I) a description of basic advances in chemistry, ° W M o n
especially synthesis, of parathyroid hormone ;II) studies of biosynthesis, " h 0
secretion and metabolism of parathyroid hormone and calcitonin with special 3a a ,.g
eWphasis on pertinent information concerning the complex, heterogeneous nature to
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of circulating forms of hormone in blood which interfere with measurement of W W r
active hormone and newer assay methods developed to circumvent these difficulties ; ... N o r,!
III) studies in the photobiology, metabolism and assay of vitamin D and its W .1 ^o c++
metabolites essential to understanding the consequences of environmental flight Lr n
exposure and the regulation of vitamin D action on skeletal mineral. 00 —to r
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I.	 Chemical Studies of the Polypeptide Hormones n
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A.	 Sequence Analysis a rn
Newer methods permit accurate sequence analysis to be carried out on o,
extremely small amounts of material, an essential requirement for work with,
for example, human parathyroid hormone which is available in only very limited a	 t°
quantities.
	
Use of radioisotopes to increase sensitivity has proven effective; ^
a) labeling of histidine and tyrosine residues with radioactive iodine. 	 This N
permits identification of these residues in picomole gt.:ntities of peptide. 	 The
procedure has proven useful in the characterization, by Edman degradation, of
parathyroid peptide fragments in plasma using the labeled tyrosine residue at
position 43 as a marker; b) internal labeling of parathyroid peptide. 	 by V. aaincubation with tissue slices in vitro.	 The appropriate	 C and/or	 -labeled rn 1
amino acids are introduced into the tissue incubation medium, after which the
peptides are purifier by standard techniques in presence of carrier hormone to
improve recoveries of labeled hormone. 	 The labeled amino acids are identified
during sequence analysis by detection of radioactivity in the phenylthiohydantoin
derivative.
	 This method was employed in the sequence analysis of human para-
thyroid hormone, recently completed in our laboratory, and in the structural
analysis of the ribosomal precursor form (pre-proparathyroid hormone). Figure 1.
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2Previous work in this laboratory has established the amino-acid sequence of
parathyroid hormone from the bovine and the porcine species. More recent work has
been directed toward completion of the sequence of the human hormone. Since the
hormone must be extracted from pooled adenoma tissue removed at surgery, the
quantities of material available for structural work is extremely small, placing
a particular premium on the high sensitivity methodology just described. To
date we have established 80 out of the 84 sequence positions in the molecule.
Figure 2.
B. Synthesis
Polypeptides varying in length from six to forty amino acids have
been synthesized in our laboratory employing the solid-phase technique.
Rigorous monitoring of syntheses as they progress, as well as the sequential
application of several purification modalities has made solid-phase synthesis
an extremely valuable and reliable tool for endocrinological investigation.
Two broad areas have been the subject of this laboratory's research: (1)
the synthesis of fragments of the natural sequence of parathyroid hormone, and
(2) the synthesis of analogues of parathyroid hormone containing structural
alterations, such as amino acid substitutions with naturally, modified, and
non-naturally occurring amino acids. The latter category has made possible exten-
sive structure-function studies as well as providing information about the
structural requirements for inhibition or antagonism of parathyroid hormone.
Previous research by this laboratory defined the minimum sequence length of
parathyroid hormone, an 84-amino-acid polypeptide, necessary for biological
activity (as demonstrated in the in vitro renal adenylyl cyclase assay). This
region comprised the NH2-terminal amino acids 2 through 27. The amino-terminal
sequence 1-34 contains all the requirements for biological activity equal to
that of the native hormone. Because the synthesis of the 34-amino-acid, fully-
active fragment of parathyroid hormone can be readily performed by solid-phase
procedure, it may have important clinical and therapeutic uses. Current
studies performed in collaboration with Dr. John Parsons and colleagues at the
Medical Research Council in Great Britain suggest a possible beneficial role
of parathyroid hormone in the treatment of osteoporosis '. Because native human parathy-
roid hormone is available"iff only minute quantities, these studies must rely on syn-
thetic hormone. Obviously, the design and'synthesis of super-potent analogues of para-
thyroid hormone would be of great advantage.
An analogue of bovine parathyroid hormone containing two structural alterations
at the carboxy terminus of the 1-34 fragment was synthesized. Tyrosine was sub-
stituter' for phen- ?ala.nine at position 34, and the carboxy-terminal carboxylic acid
group was changed to the amide function to yield {Tyr34)bPTH(1-34 amide). The
activity of the analogue is nearly twice that of the natural sequence, bPTH (1-34).
Whether the increased potency is due to facilitated receptor binding or increased
resistance to degradation remains to be established.
Previous studies in this laboratory have also defined some of the structural
requirements for inhibition of parathyroid hormone. The sequence 3-34 lacks the
amino-terminal residues required for biological activity in the renal adenylyl
cyclase assay, yet it acts as a competitive inhibitor of hormone action. Hence,
a dichotomy between receptor binding and adenylyl cyclase activation was demon-
strated by deletion of only two NH2 terminal amino acids. Suspecting that super-
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potent analogues of parathyroid hormone might provide the structural features
necessary for "super-potent" antagonists of hormone action, an analogue con-
taining the C-terminal tyrosine-amide substitution as well as the NH2-terminal
amino-acid deletions, {Tyr3 4)bPTH (3-34 amide), was synthesized. Similar analogues
lack'ng methionines at positions 8 and 18, and hence sulfur-free,{Nle 8, Nlei8,
Tyr3t )bPTH(3-34)and {N10, N1e 18 , Tyr34 )bPTH • (3-34 amide) were also prepared. These
analogues are currelitly being evaluated. -Powerful hormone antagonist properties
of these. compounds.have.been confirmed in the in vitro adenylyl cyclase assay.
Studies have been undertaken toward the development of a membrane-receptor
binding assay, based on the binding of radiolabeled parathyroid hormone to
receptor sites in renal cortical membranes. This approach necessitated the
design of an analogue of parathyroid hormone resistant to oxidation and
containing a radioiodine attachment site outside the sequence region 2-27
known to be critical for biological activity. Bovine parathyroid hormone
contains two methionine residues, one at position 8 and one •It position 18.
Oxidation of the 84-amino-acid parathyroid hormone molecule or the active
fragment results in dramatic loss of biological activity because of the for-
mation of sulfoxide and sulfone groups at the methionine residues, which pre-
sumably interferes with receptor binding. Since oxidation is inherent in con-
ventional iodination techniques, radioiodination of parathyroid hormone to
high specific activity to produce a biologically active tracer suitable for
receptor binding studies is virtually impossible. An analogue of the 1-34
active fragment of the molecule was designed containing isosteric substitution
of methionine with norleucine at positions 8 and 18, and with tyrosine substi-
tution for phenylalanine at position34, in order to direct iodine attachment
to the C terminus. The analogue Me g , N1e18 ,Tyr34 )bPTIfl(1-34) was found to
be 76% as potent as the fully active fragment bPTH(1-34). After iodination of
90% of the tyrosine residues, there was no decline in biological activity.
Besides providing a suitable analogue to serve as a tracer for membrane bind-
ing studies, this derivative demonstrates that methionine is not essential for
biological activity, although oxidation of methionine drastically impairs
biological activity.
However, a suitable preparation of membrane-receptors has not yet been
satisfactorily accomplished. Rat renal cortical membranes contain large numbers
of low affinity, high capacity sites, as well as high degradative capabilities.
Further work with membranes of other species and other purification techniques
for isolation of receptors is underway. Particularly promising are our initial
studies with high purified bovine renal cortical membranes.
Synthetic polypeptides representing specific regions of the hormone have
been prepared by the solid-phase procedure. The C-terminal fragment of bovine
parathyroid hormone, bPTH(53-84) has been synthesized. This peptide will also
be evaluated for bioactivity or antagonist activity in multiple systems, and will
be used for immunization purposes. The synthesis of a hexapeptide representing
the unique sequence of proparathyroid hormone (-6-(-)1) has been achieved. The
role of this highly basic hexapeptide and its degradative metabolites in the
regulation of parathyroid hormone biosynthesis and secretion is under study.
Recently, we have also completed the synthesis of the preproparathyroid hormone
specific peptide of 25 amino acids. The generation of antibodies specific to the pre-
proparathyroid hormone, prohormone,NH2-terminal, and C :-terminal regions of the molecule
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have now been accomplished or are in progress. These newer assays based on
antibodies directed against selected portions of the hormone and its precursors
and their application to improved methods of detection of normal and abnormal
states of parathyroid hormone secretion are discussed in Section II below.
II. Biosynthesis, Metabolism, Control of Secretion of Parathyroid Hormone and
Calcitonin: Application of the Radioimmunoassay to Clinical Disorders of
Parathyroid and C-cell Function
During the past year we have made substantial progress in our studies
of the biochemical mechanisms and the controlling factors involved in the
biosynthesis, secretion and metabolism of parathyroid hormone. Further studies
of the pre-proparathyroid hormone, the major product that we have identified,
of the translation of parathyroid messenger RNA in cell-free systems, indicate
that the pre-hormone is the initial protein-product of the gene for parathyroid
hormone. Proparathyroid hormone, the biosynthetic precursor identified by our
group previously,is now recognizes: to be an intermediate between pre-proparathyroid
hormone and parathyroi: hormone. 1.1vestigations have continued on the nature
and origin of the circulating peptidt fragments of parathyroid hormone, and new
insight has been gained regarding the -ole of the kidney in the metabolism of
the hormone. Further refinements and developments have been made in the
radioimmunoassays for the parathyroid ho.-none and Calcitonin. A sensitive assay
has been developed for the detection of human proparathyroid hormone, for the
prohormone-specific hexapeptide, and also for the biologically active amino-
terminal sequence of human parathyroid hormone. The immunoassay for Calcitonin
has been improved and applied to the measurement of Calcitonin in the blood
of patients with thyroid and nonthyroid (lung) malignancies. These studies have
led to a deeper understanding of the processes responsible for and the diagnosis
of clinical disorders of parathyroid and C-cell hyperfunction in man through
more critical interpretation of radioimmunoassay measurements.
A. Radioimmunoassay of Human Proparathyroid Hormone: Analysis of
Hormone Content in Tissue Extracts and in Plasma
We have developed a radioimmunoassay for human proparathyroid hormone
(hProPTH) and have applied it to an evaluation of prohormone content in para-
thyroid tissues and in plasma. Antisera were produced in rabbits by immunization
with a synthetic oetadecapeptide fragment of bovine ProPTH (bProPTH). A
synthetic analogue of the prohormone peptide fragment containing tyrosine was
used as the radioiodinated tracer, and a synthetic prohormone peptide consisting
of the first 40 amino acids of hProPTII was used as the assay standard. The
immunological activity of synthetic hProPTH peptide was unstable in plasma and
buffers containing plasma or serum, but degradation was prevented by using heat-
inactivated serum and EDTA in the assay solutions. The sensitivity of the assay
for detection of hProPTH peptides (0.2 ng) was 5,000-times greater than for the
detection of cross-reacting parathyroid hormone (PTH) peptides (lag), and the
prohormone-specific hexapeptide did not react in the assay. The amounts of
ProPTII in extracts of freshly-collected human parathyroid adenomas and in extracts
of bovine parathyroid glands were 0.35 + 0.13 and 0.38 + 0.13 ug/mg protein,
respectively, whereas the amounts of ProPTH in extracts of adenomas stored for
up to a year before extraction and in extracts of human parathyroid glands
obtained at autopsy were approximately ten-times less than in freshly-collected
and extracted tissues. PTH in parathyroid adenomas (0.32 + 0.14 ug/mg tissue
protein) was much less than it was in bovine parathyroid glands (4.96 + 1.34);
in parathyroid adenomas, ProPTH contributes 501, of total immuroreactive glandular
hormone compared with 7% in bovine parathyroids. No prohormone was detected in
5parathyroid venous effluent blood (<2.0 ng/ml) under conditions in which ProPTH
was shown to remain immunologically stable. PTH levels in effluents were
estimated separately and found to be as high as 190 ng/ml. Thus, ProPTH, if
released, can only comprise less than 1-2% of the secreted immunoreactive hormone.
Although studies of prohormone content in parathyroid tissue under various
E	 circumstances may provide important information concerning biosynthetic
!
	
	 mechanisms, it does not appear likely that assays for proparathyroid hormone
will be helpful as markers of parathyroid-gland secretory activity.
B. Radioimmunoassay of Preproparathyroid Hormone
With the recent successful synthesis of the 25 amino acid peptide
specific for the preproparathyroid hormone (figure 1) intensive efforts are
now underway to develop by methods used successfully with our other synthetic
peptides, an immunoassay for the initial glandular form of the hormone. Certain
evidence, particularly that relating to unusual immunoreactivity of circulating
hormone in patients with parathyroid-hormone-like humoral hypercalcemia
secondary to malignant tumors of various types, suggests that under certain
conditions the preproparathyroid hormone may be secreted into the circulation.
If this is true, assays for this precursor form may provide an alternate
approach to more accurate delineation of abnormal gland functions.
C. Radioimmunoassay of Parathyroid Secretory Protein
The high molecular weight polypeptide, parathyroid secretory
protein (PSP), identified earlier by one group as a molecular entity of unknown
function but under absolutely parallel control with respect to parathyroid
hormone regarding calcium effects on glandular secretion in vitro represents
an alternate approach to monitoring of parathyroid gland function.
Recently, sufficient of this polypeptide has been isolated to develop a
radioimmunoassay for its detection. Preliminary studies indicate that PSP
is secreted in vivo and hence clearly represents yet another alternate to
detection of glandular secretion activity.
D. Metabolism of Amino- and Carboxyl-Sequence Immunoreactive Parathyroid
Hormone in the Bovine: Evidence for Peripheral Cleavage of Hormone
Several studies have shown that the immunoreactive heterogeneity
of parathyroid hormone (PTH) in blood, first described by Berson and Yalow,
is due to the presence in blood of one or more immunoreactive fragments of PTH
-.
The use of sequence-specific radioimmunoassays for PTH indicate that the
predominant form of PTH in the circulation of patients with hyperparathyrc•'.;tism
and in dogs after intravenous injection of bovine PTH is a large fragment
of the hormone that consists of the middle and carboxyl two-thirds of the hormonal
polypeptide and lacks the amino-terminal sequence required for biological activity.
Some, but not all, investigators have found, in addition to the large C-fragment
of the hormone, smaller N- and C-sequence fragments in blood.
Disagreement exists concerning the physiological processes leading to the
appearance of hormonal fragments in the circulation. Earlier work indicated that
the principal, if not sole, secreted form of hormone was intact, suggesting that
fragments must originate by cleavage of intact hormone at peripheral sites in
the circulation. It has been reported, however, that, in certain patients with
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hyperparathyroidism, fragments of the hormone may also be secreted from the
parathyroids. In a patient with renal failure, it was reported that, after
secretion, the fragments had a greatly prolonged existence in the circulation,
with half-times of disappearance on the order of days. These important findings
led to the introduction of the thesis that fragments found in peripheral blood
might arise largely from the gland, even though present in parathyroid effluent
at low concentrations.
To ascertain directly whether PTH undergoes cleavage to fragments at
peripheral sites in the circulation, and to further determine the clearance
rate of fragments formed, the concentrations of immunoreactive PTH in the cir-
culation of calves after the intravenous injection and infusion of intact
bPTH were analyzed by gel filtration and sequence-specific radioimmunoassays.
We have utilized radioimmunoassays that detect specifically peptide se-
quences with either the biologically active amino region (N-assay) or in-
active carboxyl region (C-assay) or parathyroid hormone (PTH) to evaluate the
metabolism of PTH during and after infusion and injection of homogenous
(containing less than 0.1% hormonal fragments) intact bovine PTH (bPTH) into
calves. During continuous infusions of hormone, when constant blood levels of
immunoreactive PTH were reached, a dissociation between the concentrations of
amino versus carboxyl immunoreactivity was observed; concentrations of hormone
measured by the C-assay rose to a level of approximately three-times higher than
that measured by N-assay. Analysis by gel filtration of immunoreactive PTH in
plasma samples from calves after injection of hormone showed the rapid dis-
appearance of intact hormone (N and C assays) and the appearance of a large
fragment detected by the C-assay but not by the N-assay. The hormonal fragment
lacked antigenic determinants within the amino peptide sequence required for
biological activity. No additional fragments of PTH were detected by gel
filtration using the N and C assay.. No detectable conversion of intact PTH
to hormonal fragments occurredduring incubation in vitro in bovine serum.
The results are consistent with the concept that intact PTH is metabolized
after entry into the circulation at peripheral sites located outside the
vascular space, resulting in the rapid disappearance from blood of intact
hormone and the appearance of a biologically inactive hormonal fragment(s).
These studies done in calves agree with earlier studies done in dogs and man
and point to the existence in mammals of common pathways for the peripheral
metabolism of PTH.
E. Metabolism of Parathyroid Hormone in vivo
Recent findings in parathyroid research have led not only to im-
proved understanding of parathyroid physiology but also to confusion and
uncertainty in parathyroid-related physiological and clinical research due to
recognition of complexity in hormone metabolism. Multiple forms of PTH have
been detected in the circulation. Present evidence suggests that some, but
not necessarily all, of these multiple forms of circulating PTH represent
peripheral cleavage of the intact PTH once the hormonal polypeptide is secreted.
Since studies of the synthesis of amino-terminal fragments of the PTH poly-
peptide have suggested that there are biologically active fragments containing
7only 27-34 amino acids out of the total 84 residues present in the native
hormone, some of th^ circulating fragments of hormone might be biologically
active. Conflicting reports have appeared from various laboratories con-
cerning the absolute concentration and the rate of metabolic turnover of
PTH in the circulation, particularly in primary and secondary hyperpara-
thyroidism. These findings, which have clouded interpretation of immuno-
assays in clinical studies, undoubtedly relate to the complexity of forms
of circulating endogenous hormone. We have concluded, therefore, that
despite the great advances made in chemical analysis of parathyroid hormone,
there is considerable uncertainty as to the precise chemical nature of the
chemical species of hormone active at receptors in bone and kidney, and
the hormonal species actually measured as immunoreactive parathyroid hormone.
Since last year's report, considerable progress has been made in under-
standing the nature of this heterogeneity of circulating parathyroid hormone
and in ascertaining the significance of metabolism of parathyroid hormone.
Information from several laboratories concerning the heterogeneity and
metabolism of parathyroid hormone contain many areas of agreement and several
areas of disagreement. Our studies of exogenous hormone administered to cows,
dogs, rats and man have demonstrated that parathyroid hormone undergoes
metabolism after secretion. However, other reports suggest that fragments
are also secreted from the gland.
A second issue r?lates to the number and nature of the circulating frag-
ments. All laboratories agree that the dominant circulating immunoreactive
form of the hormone is fragments which comprise the middle and carboxyl
portions of the sequence and, therefore, must be biologically inert. Intact
hormone contributes no more than 25% of the circulating imnunoreac:tivity.
In addition, evidence presented by other groups has indicated that there
may be other, still smeller immunoreactive forms of parathyroid hormone in
the circulation. One of these, with an estimated molecular weight of approxi-
mately ^_000, has been reported in the plasma of some patients with chronic
renal failure. Another, with an estimated molecular weight of 4500, has been
recovered from concentrates of human plasma and has been reported to be
biologically active in the rat renal cortical adenylyl cyclase assay. This
latter finding, if confirmed, is obviously of considerable significance.
Thus far, however, in studies in our laboratory, we have not detected the
presence of these two smaller forms of the hormone, despite the use of
multiple antisera in the radioimmunoassay of fractions from gel filtration of
endogenous hormone from man and cow and of exogenously-administered bovine
PTH in dogs. The reasons for this discrepancy are not clear. Our studies
have led to the conclusion that cleavage of the intact hormone after secre-
tion may result in the generation of a biologically-active NH2-terminal
fragment. Such a fragment, our studies indicate, must circulate at very low
concentrations,if at all. Therefore, it would seem possible that the
concentration process used by Canterbury and Reiss may have resulted in their
ability to detect an NH2-terminal fragment.
We have used two approachs , to further explore whether fragments other than the
large middle-carboxyl terminal fragment circulate--par`^cularly amino-terminal fragments.
8In one approach, we have concentrated circulating hormone by affinity
chromatography and carefully examined the concentrate for fragments, including
amino-terminal fragments. Anti bovine PTH and anti-bovine PTH ( 1-34) aa a-
sera have been coupled to Sepharose after it has been activated by cyanogen
bromide. After exposure of the ligand-resin to large volumes of patient
plasma, approximately 50% of the total immunoreactivity in 240 ml of plasma
can be recovered in approximately 3 ml of eluate, resulting in a 40-fold
increase in concentration. Gel filtration and analysis using sequence-
specific radioimmunoassays has not demonstrated the presence of any circu-
lating fragments other than those seen prior to concentration. Specifically,
no amino-terminal fragments were detected.
In a second approach, we have attempted to circumvent the difficulties
intrinsic to immunoassays by using internally-labeled hormone containing
specific radioactive amino acids to identify different portions of the para-
thyroid hormone sequence. Sufficient quantities of highly-purified,
internally-labeled bovine PTH have been prepared to permit a series of in vivo
experiments in rats. The approach looks especially promising but has not
yet definitively settled the issue of circulating amino-terminal fragments.
Although our data suggests that, at least using pharmacological doses
of hormone in the rat, amino-terminal fragments can be detected in circulation,
it	 still uncertain whether amino-terminal fragments circulate under
phys=iologic conditions.
These results have also somewhat hindered the development of new assays
to measure intact hormone, exclusively (see below). It is still not clear
whether such assays will require only assay systems to measure the amino-
terminal portion of the sequence or whether techniques such as the "sandwich
assay" will be necessary. Methods have been developed for iodination and
purification of labeled antisera and for lessening and non-specific adsorp-
tion of the labeled antisera to the solid-phase support used in the"sandwich
assay". However, the priorty of this project is uncertain. Our hypothesis
is that measurements using antisera that recognize amino-terminal determinants
will accurately reflect the circulating concentration of intact hormone.
Accordingly, emphasis has shifted toward attempts to develop suitable anti-
sera by immunization, and to improving and streamlining the application of
affinity chromatographic concentration of the various immunoreactive species.
Nevertheless, the sandwich approach will serve as a valuable alternative
assay method which, at minimum, will be available to confirm the results
obtained using other methods.
An additional issue relates to the question of whether hormonal metabolism
is of importance in establishing the circulating concentration of biologically
active hormone. Accordingly, studies have also been initiated to examine
whether physiologic perturbations of the state of the animal alter the pattern
of metabolism. In preliminary studies, circulating calcium concentrations
were acutely altered by calcium or EDTA-infusions after steady-state con-
centrations of immunoreactive hormone had been achieved during infusion of
bovine PTH. These acute perturbations did not alter the concentrations of
immunoreactive hormone in circulation.
Studies have been initiated with both radioiodinated and cold bovine PTH,
in order to explore not only the effects of acute perturbations in the serum
calcium on metabolism of the hormone, but also hormone metabolism in a number
of chronically perturb ated models. These models include parathyroideetomized-
hypocalcemic-dogs maintained with vitamin D, parathyroid-intact, -vitamin D-
deficient, hypocalcemic dogs,,paratbyroidectomized, -vitamin D intoxicated,
-hypercalcemic dogs, and parathyroid-hormone-infused, -vitamin D-intact,
-hyperca.lcemic dogs.
In addition we have studied the nature of the iodinated and internally-
labeled hormone fragments that are present in the liver and kidney after
injection of the hormone has Ibeen studied in the intact rat, at time intervals
of from 2 to 96 minutes after injection.
Identification of fragments in kidney and liver by sequence analysis of
the radioiodinated fragments at early time intervals has shown that whereas
the radioactive fragments in the liver are identical to those in circulation,
those in the kidney are different. Particularly at the earliest time intervals,
the kidney contains only the fragment cleaved between residues 38-39, a
fragment not seen in circulation. The significance of this observation is
not clear, but suggests that the liver may be the principal organ contributing
to the circulating fragments.
F. Summary- Present Achievements and Future Directions ^nthe Development
of Improved Radioimmunoassays for Parathyroid Hormone and Application
to Man
Figure 3 illustrates the known or possible products of the
parathyroid gland secreted into the blood in vivo. As described above assays
are being developed for each of the potential secretory products of the gland.
These assays may provide direct approaches to assessment of the secretory
activity of the parathyroid, independent of the confusion presently introduced
by variable detections of fragments of the hormone itself. The results with
the assay for PSP already shows great promise; others are being evaluated.
Alternate approaches are our present efforts to develop radioimmunoassays
that will detect intact hormone, bPTH 6-(l-84), exclusively. The major effort
is directed toward the development of assays with the extraordinarily high
sensitivities required to measure the small concentrations of circulating
hormone with amino-terminal reactivity. If our results are correct, such
assays will measure intact hormone, exclusively. Alternatively, if we find
amino-terminal circulating fragments, the antisera developed which recognize
determinants in the amino-terminal portion of the sequence will be used in
conjunction with antisera that recognize.only carboxyl-terminal determinants
in a "sandwich assay".
Attempts to produce assays which measure only amino-terminal determinants
by using tracers of synthetic fragments (bovine PTH 1-34 and 1-33 [tyr34] )'
have thus far yielded assays that are not sensitive enough to measure
circulating concentrations in man. Efforts using a number of synthetic fragment
analogs (i.e. - with "spacers" between the tyrosine residue and the remainder
of the sequence) will be initiated later this year.
In addition, immunizations have recently been initiated using the synthetically-
prepared peptide of human PTH--which extends from residue 53-84. The antigen de-
veloped will be useful in measuring the carboxyl portion of the sequence and, of
coursel will be essential in the development of the "sandwich assay".
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These assays will be particularly useful for measuring intact hormone and
therefore should detect the immunoreactive hormone in circulation which more
accurately reflects parathyroid secretory activity than the present assays
which all measure the dominant circulating form of the hormone, the large,
biologically-inactive fragment which results from metabolism of the originally
secreted hormone.
III. Vitamin D Hormone Metabolism and Assay of Active Metabolites
Studies on vitamin D production in skin, its circulating concentration
in plasma, its hydroxylation to 25-hydroxyvitamin D by the liver and improved
assays for active metabolites are all under study.
A. Production of Vitamin D in the Skin
Vitamin D is produced in the skin by the action of ultraviolet
radiation on a precursor 7-dehydrocholesterol. The vitamin is also present, as
a supplement to the endogenous source, in food. Vitamin D intoxication has
been shown to occur with oral consumption, but not with U.V. exposure, thus
leuding to the postulation that some natural mechanism must exist in the skin
-..o prevent intoxication by U.V. radiation.
In an effort to explore this theory, several preliminary experiments have
been carried out. In the first, skin biopsies were taken from pigs given U.V.
Irradiation. In these samples, an increase in skin content of vitamin D seemed
t*) occur as the length of exposure to the radiation increased, and this increase
in the vitamin concentration seemed to occur mainly in the subcutaneous fat
layer. However, the technical problems which arose in the extraction of the
small amounts of vitamin D from the other neutral lipid in the skin samples have
made this method of studying vitamin D production in skin less immediately
useful, and another approach has been made.
Work using radioactive precursors of vitamin D, specifically 7-dehydrocholes-
terol, has led to systematic analysis of the products resulting from U V irrad-
iation) (See attached preprint). This work permits dissection of the con-
trolling principles believed to operate in.skin tc foster vitamin D productions%
yet prevent D intoxication.
B. Studies on Tissue Receptors for Vitamin D Metabolites
It has been shown that the rat intestinal cytoplasmic vitamin D
2•eceptor is a single, monomeric, 5.5S protein with M.W. 80,000, which is
negatively charged at physiologic pH and is clearly aeparable from the correspond-
ing serum-binding protein by sucrose-gradient ultracentrifugation and by
ion-exchange chromatography. Rapid loss of binding activity of 4 0C can be
prevented by protease inhibitors, and pH, temperature and ionic-strength
binding optima have been defined. While results to date suggest a three-fold
greater avidity for 25-HCC than for 1,25-HCC, accurate definition of binding
specificity awaits further improvement in the assay technique. Notably,
most of these results are quite unlike hose obtained from study of the hgian
intestinal receptor by Haussler et al.
Examination of cytosols from a wide variety of rat tissues, including
many not presently considered "target organs" of vitamin D action, disclosed
the presence in each of a single receptor which is indistinguishable from
the intestinal receptor by ultracen^.rigugation or disc-gel electrophoresis and
which, like the intestinal receptor, is labeled after in vivo administration
of 11 3-25-FiCC as well as in in vitro studies with H 3-25-HCC or H3-1,25-DIICC.
These results confirm and extend those of Haddad et al.,and suggest that vitamin D
may participate more fundamentally in cellular metabolism than has previously
been inferred from its known effects on calcium and phosphate homeostasis.
C. Development of an Assay for 1,25-(OH) -D
The development of an assay for the active metabolite of vitamin
D, i.e., 1,25 (OH)2D3, has been a subject of much interest. Both the intestinal
receptor and the plasma vitamin D-binding protein have high affinities for
	
l
the metabolites, but in each case the affinity for 25-OH-D metabolite is as
great if not greater. Therefore, separation of these two metabolites i-.,
a necessary step in any assay. This separation was envisaged as beinC , possible
on the high pressure liquid chromatography system, but in the original
experiments the lipid content of the plasma extracts was too great for the
chromatography columns in this system. However, a method of separating this
neutral lipid from the polar metabolites in serum is available, and may allow
the apl lication to this effective separation system of polar fat-soluble
serum 1:omponents alone and not the overload of neutral lipid. This approach
will ..:eke the assay of the active metabolite 1,25-(OH)2D available as a
routine, specific, rapid assay.
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PI1O'202•02ABOLISM OF 7-DE'.1YDROC:iOLE3TEROL TO PREVITIUMIN D 3 IN SKIII
N.F. Holick, J.E. Fromner, S.C. McNeill, N.M. Richtand,
J.W. Henley, and J.T. Potts, Jr.
Department of Nedicine, Har'raa •d f.edical School, and Endocrine
Unit, Massachusetts Cenernl hos pital, Boston, Mass. 02114
SU.:WRY: The photometabolism of [3a- 3H] -7-dehydrocholesterol in skin Was
studied in groups of rats exposed to ultraviolet irradiation. The major
photolytic product was identified as previtamin D 3 by its identical migration
with authentic previtamin D33 on high-pressure liquid chromatography.
Furthermore, this photometabolite was isolated in pure form from endogenous
precursors in skins of rats exposed to ultraviolet irradiation; identification
as previtamin D3 was based on its ultraviolet absorption spectrum, mass
spectrum and its thermal conversion to vitamin D3.
I:1i'RODUCTIO.t: Vitamin D, a fat-soluble factor that acts to heal rachitic
lesions, was discovered in the early 1900's (1,2). Subsequently, Steenbock
(3) and Fiess et al. (4) independently demonstrated that this factor could be i
generated simply by irradiating either rachitic animals or their food.
Further work led to the isolation and structural identification of vitamins
D2 , D39 and their precursors, ergosterol and 7-dehydrocholesterol, respectively
( 5-7)
Photolysis of ergosterol or 7-dehydrocholesterol in vitro yields,
at equilibrium, at least three isomeric products: tachysterol, lumisterol,
and a 9,10-seco-steroid with a 5,6-cis-triene conformation. This latter
compound was shown to have antirachitic activity and, depending on the
starting; material, ergosterol or 7-dehydrocholesterol, was named vitamin
DI, or vita..-,in D3 , respectively. At first it was believed that 7-dehydro-
cholesterol and ergosterol were converted directly to vitamin D3 and
vita^in D2 by ultraviolet photolysis (8). In 1949, however, Velluz et al.
(9) demonstrated that a 6,7-cis isomer, which. they named previtamin D,
was the initial irradiation product a-id that, at varying rates as a function
of tc:aperatu_rc, previtwnin D converted to vitamin D with the equilibrium
in favor of vitamin D. Thuz,, u:nder controlled coalitions, ultraviolet
X)bre:, iatUior::;: KPLC, Iii(-,h-Pressure Liquid Chromatography; TLC, Thin Layer
Chromatography
irr-wiution of 7-d ,^hydrocholeaterol generates three major products:
ta.chysterol, lunisterol, and previtamin D 3
 (Fig. 1). Previtamin D3 is
then converted to the thermodynamically favored 5 ,6-cis iscmer, vitarrain D3,
by thermal equilibration.
Although it has been generally accepted that vitamin D 3
 is generated
in vivo by ultraviolet irradiation of the 7-dehydrocholesterol in the skin,
the mechanism by which this occurs has not been investigated. We have
examined this mechanism and clearly demonstrated that 7-dehydrocholesterol
is initially converted to previtamin D 3 in the skin in vivo, as it is in
the test-tube model, by the action of ultraviolet light.
i4ETHODS :
Synthesis of [3a-3H]-7-dehydrocholesterol. Synthesis of this isotope was
carried out as described for [3a- 3H]-ergosterol (10). Crystalline 7-dehydro-
cholesterol was oxidized to 4,7-cholestadiene-3-one (amax 240 nm) by the method
of Shepherd et al. (11). This a-S unsaturated ketone was acetylated with
acetic anhydride and pyridine, and the isolated product exhibited Amax 331,
316, and 303 nm, which is characteristic for the A5 ,7-enol acetate. The enol
acetate ( 10 mg) was dissolved in 10 ml isopropanol containing 100 µl H2O
and to this solution was added 1 mg . [ 3H)-sodium borohydride ( S.A. 8.0 Ci/e,!)
purchased from New England Nuclear, Boston, Massachusetts. The mixture was
stirred at 25°C for 2 h and then extracted with ether:water. The product
was dried under N2
 and applied to preparative thin-layer chromatographic
plates (Uni,late, Analtech Inc., Delaware) and developed in n-hexane:
ethyla .cetate ( 8:2 v/v). The compound with an Rf of 0.6 was eluted and
exhibited an ultraviolet spectrum with 1ma.x 295, 282, and 271 nir., which is
identical to the ultraviolet spectrum for 7-dehydrocholesterol. (10).
Furthermore, this product migrated identically with authentic 7-dehydrochol-
esterol on thin-layer chromatography (TLC) and on high-pressure liquid
chromatography (HPLC) using a 0. 1E-mmx30-cm u-Porasil colw n developed with 1%
isopropanol in n-hexane. An additional product with an identical ultraviolet-
absorption speetrLw. but with an R f
 of 0.8 was also recovered; the latter
did not migrate with 7-dehydrocholesterol on HPLC or TLC. This additional
compound was presumed to be [ 3- 311 ]-3-epi-7-dehydrocholesterol, a predicted
side-product of the reduction reaction.
5'.opicnl application and irradiation of [3a- 311]-7-dehydrocholesterol. Area:
(3 X ; cm) of the backs of two groups of vitamin-D-deficient rats were shaves.
Two uCi of [3a- 3111-7-dehydrocholesterol dissolved in 0.1 ml of V esson oil
110 .s ',Plied to this exposed skin 24 h after shavin . The control group was
kept in the dark; the treatment group, after an additional 24-h delay, wa,
pliccd under an ultraviolet li[;:it of *,rave-length 250-350 nm for 3 h
(0.23 ,joules/cn2 fit 1 280 nn ). Immediately after irradiation of thF_ treatme:;t
all a.nimi^al.; were killed by exsar.guination, and the 3X3-cm area of skin
:^..; r^ -W)'It d and frozen on Dry Ice.
2.
-lsoleticn end identification of radioactive photolysis products. Individual
skins w:re homogenized in 10 ml 0.9%saline with a Polytron homogenizer for
30 sec and extracted with 40 =1 cholerform:methanol (1:1). The cholorform
phase was collected, and the aqueous phase was re-extracted twice with 10 ml
chloroform. The chloroform phases were combined, dried under N2 at 4°C,
dissolved in n-hexane:chloroform (19:1), and applied to a lx6G-cm glass column
packed with 15 grass of a Neodox -1518 alkoxyl derivative of Sephadex MI-20
prepared according to the procedure of Ellingboe et al. (12). The column was
eluted with n-hexane: chloroform (19:1). Fractions (2 ml) were collected,
dried under air, and dissolved in Irstagel (Packard) prior to counting of
their tritium content in the Packard Triearb 3375 scintillation counter.
The various peaks of radioactivity were identified by taking individual
peak fractions from the Neodox column and subjecting them to chromatography
simultaneously with standard compounds on HPLC equipped with a 0.4-cmx30-cm
u-Porasil column using 1% isopropanol in n-hexane as solvent. The peak
assigned as previtamin D3 was mixed with 100 yg authentic previtamin D
chromatographed on HPLC as described above, and collected in 1-ml fralons.
Half of each fraction was dried and counted for tritium. The remaining fractions
containing the previtamin-D3 peak were pooled and warmed at 60 0C in methanol
for 3 h before re-chromatography on the same column under identical conditions.
Isolation and identification of a sterol formed from photolysis
 of endoxenous
T-dehydrocholesterol. 50 rats previously maintained on a vitamin-D-deficient
diet for 3 weeks were shaven as before. 24-h later they were exposed to
0.23 joules/ =2 at x280 nm of ultraviolet light over a period of h and
then immediately killed by exsanguination. Topical doses of [3a--3H]-T-
dehydrocholesterol were applied to 3 rats as described above, before irradiation,
to act as a radio-active marker. The shaved skin from all animals was
collected, homogenized and extracted as previously described. The extract
was dried under N2
 in the cold room. and the lipid residue was re-extracted in
800 ml vater:n-hexane (1:1). The n-hexane phase was collected, and the
aqueous phase was re-extracted twice with 100 ml n-hexane. The n-hexane
phases were combined and dried under 1-1 2 at 4°C, and the residue was dissolved
in n-hexane:chloroform (19:1) and applied to a 3x40-am glass column packed
with 60 g Keodox-1518 derivative of Sephadex LH-20 in the same solvent.
The previtemin-D3 peak was collected, dried under N2 , redissolved in 10 ml
methanol, and warmed at 60°C for 3 h. The product was applied to the HPLC,
and 50 ul from the resulting 1-ml fractions was counted for tritium.
Ultraviolet-ebsorption spectra were made on the previtamin-D3
 peal: before
and after heating, on a Beckman D3-G spectrophotometer.
RESULTS: The chromatographic profiles of the skin extracts from animals
given topical applications of [3a-34-7-dehydrocholesterol and then exposed to
0.23 joulea/cm2 ultraviolet radiation (A) or confined in the dark (B) are
shown in Fig. 2. The chromatogram from the confined animals shows three
peaks. The earliest peak (fractions no. 10--20) is preswaad to be an ester(s)
of the starting material. She two additional peaks were tentatively identified
L:; '[--dehYdrocholcsterol and its A7 reduction product, cholesterol. this
identification was confirmed by cochromatography with authentic compounds
on HPLC. The chromatogram from animals that received ultraviolet irradiation
demonstrated one additional major peak labeled as previtamin D 3 (Fig. 2B).
The identification of this radioactive peak as previtamin D3 was established
by (i) identical mobility with authentic previtamin D 3 on the high-resolution
HPLC system and (ii), after warming, identical mobility with vitamin D 3 formed
by thermal conversion of authentic previtamin D 3 (Fig. 3).
DISCUSSION: Although it has been generally accepted that vitamin D 3 is made
in the skin by the action of solar ultraviolet irradiation.on 7-dehydrocholesterol,
the mechanism by which this occurs has never been investigated. In this paper
we present evidence that 7-dehydrocholesterol in the skin is converted to
previt =- in D3 and not vitamin D3 , a result similar to that seen in vitro.
This was demonstrated by two methods. In the first, [3a-3H]-7-dehydrocholesterol
applied topically was converted to a compound that migrated identically with
authentic previtamin D3 on high-resolution separation systur.s. The concern
that topically applied 7-dehydrocholesterol might not enter epithelial cells
where the photolytic reaction naturally occurs was lessened when it was
demonstrated that cholesterol was generated from its precursor 7-dehydro-
cholesterol. Therefore, at least some of the 7-dehydrocholesterol had to
enter viable epithelial cells for the 7-dehydrocholesterol-z • educ`.,ase to work.
It could be argued, ho:rever, that the photolytic products recovered
were similar to those that would be found if we applied 7-dchydrocholesterol
to e piece of glass and irradiated it. Therefore, the previtamin D3 that
we observed in our isotope experir.::;nts might in fact have been an artefact
generated on the surface of the skin and nay not have entered the cells or
be a phyzioloSicc:l product.
To eliminate this po::L;ibilit.,r tin alternate approach was u:.^d. lt.!
irr.i(Iin,tcd 50 vat=a ir.-D-deficicn! rat:, and isr)J +,ed a pro:lu,^;` 	 th an
ultraviolet absorption spectrum A 
may 257 nm and A min 230 nm that was similar
to previtanin D3 (amax260 nm, Amin230 rte.). This product, formed from
endogenous 7-dehydrocholesterol, migrated identically with authentic previtamin
D3 and, when warmed at 600 , chronatographed identically with vitamin D3.
Furthermore, the product after heating had an ultraviolet absorption spectrum
amp 2265 nm, Amin 228 nm, which is identical to that of the 5,6-cis-triene
system for vitamin D3 (Fig. 4). To confirm that the isolated 5,6-cis-triene
was vitamin D3 , a mass spectrum of the isolated product was analyzed. The
compound was shown to have a molecular ion 384 (m/e) and fragments 369 (M+-CL{3),
366 ( 1 +-H20), 271 (2,:+-side chain), 253 (Id+-side chain-H20), 136 (A ring +
C6
 and C7 ), and 118 (136-H2O), which are identical to authentic vitamin D 3 (13).
In this paper we report the isolation of a photolytic product from skin
and its identification as previtamia D 3 . Therefore we suggest that the
mechanism for the photoconversion of 7-dehydrocholesterol to vitamin D3
in the skin occurs through an intermediate product, previtamin D 3 , which U.
further converted to vitamin D3 presumably by the thermal action of body
heat. Qualitative or quantitative differences, if any, in the overall process
of photolytic activation o: 7-dehydrocholesterol in vitro versus in vivo
await further study, especially the issue of biological control of the
in vivo process.
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Fts,, 1.. Photometaboliskt o: 7-dehydrocnolesterol to lumisterol, tachysterol,
and prsvit Bain v3 , which is converted to vitaiain D3 by thermal energy.
F'-t_ f:• 2. Heodox 1518 Sephadex column (1 . 60 cm packed in 19:1 n-hexane
chloroform) profiles of skin lipid extracts from animals treated with topical
application of 2 VCi [3a- 34-7-dehydrocholesterol and then killed 24 h later
(A) or irradiated with 0.23 Joules/cm2 and then killed (B).
Fig. . Chromatography of fractions 35-45 from Fig. 2B with 100 Ng of
authentic previtamin D on HPLC (A). Peak 1 was collected and warmed at
65°C for 3 h and rechr9matographed on the same column (B), which demonstrated
conversion to vitamin D3.
Fif,-, 4. Ultraviolet absorption spectrum of the isolated product from the skin
that was warmed at 650 for 3 h and chromatographed on HPLC Ls shown in :ig. 3.
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